Last reviewed · How we verify
T2,T3,T1
T2,T3,T1 is a Small molecule drug developed by Insud Pharma. It is currently in Phase 1 development. Also known as: Treatment 2-3-1.
T2, T3, and T1 are small molecule compounds that have been studied in various clinical trials for conditions such as breast cancer, post-traumatic stress disorder, acute stress disorder, dental caries, and dental occlusion. These compounds have been investigated in combination with interventions like dosage of B-type natriuretic peptide (NT-proBNP), Eye Movement Desensitization and Reprocessing (EMDR), and the Hall Technique.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | T2,T3,T1 |
|---|---|
| Also known as | Treatment 2-3-1 |
| Sponsor | Insud Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparison Of The Effects Of Regional Anesthesia On Brain And Carotid Artery Oxygenation In Shoulder Surgery (NA)
- Effect of Physical Activity Program on Sedentary of Patients With Upper Aerodigestive Tract Cancer (NA)
- Impact of Emotional Skills of Young Women and Their Partner on Adjustment to Cancer (NA)
- Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response (NA)
- Parental EMDR Therapy After a Baby's Stay in the NICU (NA)
- Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST) (NA)
- Assessment of the Locally Administrated Vitamin D3 and Corticision Efficacy on Orthodontic Canine Retraction (NA)
- Virtual Reality for Shoulder Rehabilitation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- T2,T3,T1 CI brief — competitive landscape report
- T2,T3,T1 updates RSS · CI watch RSS
- Insud Pharma portfolio CI
Frequently asked questions about T2,T3,T1
What is T2,T3,T1?
Who makes T2,T3,T1?
Is T2,T3,T1 also known as anything else?
What development phase is T2,T3,T1 in?
Related
- Manufacturer: Insud Pharma — full pipeline
- Also known as: Treatment 2-3-1
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing